title: [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
authors.affiliation: Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Japan. masikeda@east.ncc.go.jp
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Shuichi
authors.initials: S
authors.lastname: Mitsunaga
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shimizu
authors.forename: Izumi
authors.initials: I
authors.lastname: Ohno
authors.forename: Hideaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okuyama
authors.forename: Akiko
authors.initials: A
authors.lastname: Kuwahara
authors.forename: Takuji
authors.initials: T
authors.lastname: Okusaka
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib